clinical trial · NCT07002320
Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer
Institute of Cancer Research, United Kingdom·phase2·recruiting·n = 78
Metastatic Castrate-Resistant Prostate Cancer (mCRPC)SX-682Apalutamide
brief summary
ASpiRE will investigate the effect of the drug SX-682 in combination with Apalutamide in men suffering from metastatic castration-resistant prostate cancer (mCRPC).
started
Apr 28, 2025
primary completion
Oct 1, 2029
completion
Oct 1, 2029
last updated
Apr 15, 2026
official title
ASpiRE: A Proof-of-mechanism and Proof-of-concept Clinical Trial Evaluating the Safety, Tolerability, Biological and Anti-tumour Activity of Apalutamide With Dual CXCR1 and CXCR2 Blockade by SX-682 for Men Suffering From Metastatic Castration-resistant Prostate Cancer (mCRPC)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol